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a b s t r a c t
Chronic Granulomatous Disease (CGD) is a rare inherited disorder in which phagocytes fail to produce
antimicrobial superoxide because NADPH oxidase activity is absent. In about 65% of the cases, the disease
is due to mutations affecting the X-linked CYBB gene, encoding the gp91phox subunit of NADPH oxidase.
We investigated 34 CGD male patients by DHPLC and direct sequencing. A mutation was found in the
CYBB gene of 33 patients and 9 of these were novel: one non-sense mutation (c.1123 G>T), three missense
mutations (c.58G>A; c.1076 G>C; c.1357 T>A), two splice site mutations (c.141+5G>T; c.142-1G>A), one
duplication (c.42 45dupCATT), one deletion (c.184delT), and one rare deletion of two non-contiguous
nucleotides (c.1287delT + c.1290delC). One patient had the most frequent GT homozygous deletion in
exon2 of the NCF-1 gene encoding the p47phox subunit of NADPH oxidase. The carrier analysis was per-
formed in 23 patients’ mothers and 16 female relatives through molecular and FISH studies. No clear
correlation between the severity of clinical symptoms and the type of mutation could be demonstrated.
This study further supports the great heterogeneity of the disease and the notion that genetic analysis is
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. IntroductionChronic Granulomatous Disease (CGD; MIM# 306400) is a pri-
ary immunodeﬁciency that affects phagocytes of the innate
mmune system caused by defects in the NADPH oxidase system.
GD patients are susceptible to recurrent life-threatening infec-
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tions, particularly those caused by catalase positive bacteria and
fungi. In addition, CGD patients often have poorwound healing and
exaggerated inﬂammatory responses, leading to granuloma forma-
tion in subcutaneous tissues, lungs, lymph nodes, liver and bones
(Segal et al., 2000; Winkelstein et al., 2000; Martire et al., 2008).
The NADPH oxidase complex acts mainly by transferring electrons
fromNADPH tomolecular oxygen inorder to formsuperoxide indis-
pensable for killing of phagocytedmicroorganisms. This complex is
composed of a heterodimeric membrane-bound ﬂavocytochrome
b558 (formed by gp91phox and p22phox) and four cytoplasmatic
subunits: p47phox, p67phox, p40phox and Rac2. Mutations in any
of the genes encoding NADPH oxidase subunits can cause CGD.
1 Immu
A
X
p
m
e
r
s
r
s
t
y
s
s
P
e
w
2
2
G
o
C
o
e
f
y
p
a
m
n
d
(
p
e
2
p
w
m
B
t
B
C
D
2
g
a
t
i
f
w
b
2
e
l936 G. Di Matteo et al. / Molecular
pproximately two thirds of CGD cases result frommutations in the
-linked CYBB gene, encoding the gp91phox subunit. The remaining
atients with CGD have an autosomal recessive form (AR-CGD), the
ost frequent of which, is due to a mutation of NCF1 gene that
ncodes the p47phox subunit (Dinauer, 2005). Herein we report the
esults of CYBB and NCF-1 gene sequence analysis in a cohort con-
tituted by 34 CGD patients from 29 unrelated families and their
elatives andwe describe nine novel CYBBmutations. Furthermore,
ince the clinical severity of the CGD varies widely, we investigated
he correlation between the rate of severe infections per patient-
ear and the mutation type and we did not ﬁnd a statistically
igniﬁcant variation, although in patients with deletion and non-
ense mutations a higher number of severe infections were found.
olymorphisms in oxygen independent antimicrobial systems or
nvironmental factors should be investigated to ﬁnd a correlation
ith the clinical severity of the disease.
. Patients and methods
.1. Patients
Thirty-four male patients, from the Italian registry of Chronic
ranulomatousDiseasewhich is part of the Italian Primary Immun-
deﬁciency Network (IPINET), were tested for mutations in the
YBB gene. Patients were diagnosed as having CGD on the basis
f their clinical history and the inability of their phagocytes to gen-
rate reactive oxygen species (ROS) by conventional granulocyte
unctional tests as previously described (Martire et al., 2008).
Age at diagnosis ranged from 1 month to 49 years (mean 7.16
ears, median 3 years). Carrier detection was performed in 23
atients’ mothers and 16 female relatives by means of genetic
nalysis and through ﬂuorescent in situ hybridization (FISH) of
etaphase chromosomes from lymphoblastoid cell lines when
eeded.
All relevant clinical features, immunological and therapeutic
ata have been already described in a previous report by the IPINET
Martire et al., 2008). All patients were put on antiinfective pro-
hylaxis with trimethoprim/sulphomethoxazole and itraconazole
arly after diagnosis. Some subjects (patients 2, 4, 6, 8, 17, 20, 23, 24,
6–28, 32) received discontinuous administration of -interferon.
Informed consent was obtained from each studied subject or
arents of each child and all procedures used were in accordance
ith the guidelines of the Helsinki Declaration on Human Experi-
entation.
All studies were performed at the Paediatric Immunology and
iotechnology Laboratory, Tor Vergata University of Rome and at
he Department of Biomedicine of Development Age, University of
ari.
FISH studies were performed in the Lombardi Comprehensive
ancer Center, GeorgetownUniversityMedical Center,Washington,
C, USA.
.2. Cell lines
Neutrophils were puriﬁed by discontinuous Percoll density
radient centrifugation from peripheral blood of patients 17, 33
nd 34 as previously described (Giudicelli et al., 1982). EBV-
ransformed lymphoblastoid cell lines (LCL) were obtained by
ncubating approximately 5×106 PBMC, with 2ml of supernatant
rom the EBV-secreting cell line B95-8 for 1h at 37 ◦C. Infected cells
ere cultured at 1×106 cells/ml in RPMI 1640 containing 20% fetal
ovine serum, 2mM l-glutamine and 1g/ml of cyclosporin A in
4-well culture plates. Clumps of cells were usually observed at the
nd of the ﬁrst or second week and stable EBV-lymphoblastoid cell
ines were established in 3–4 weeks.nology 46 (2009) 1935–1941
2.3. Molecular studies
Genomic DNA isolated from peripheral blood of patients and
healthy controls (QIAamp DNA Blood kit by QIAGEN GmbH, Hilden,
Germany) was ampliﬁed using primers (available upon request)
ﬂanking the 13 coding exons and the promoter region of the
CYBB gene (NG 009065). PCR reactions were carried out in a vol-
ume of 50l containing 100ng of genomic DNA, 200M of each
dNTP, 0.4M of each primer and 0.5U of GoTaq DNA polymerase
(Promega, Madison, WI). The samples were denatured at 95 ◦C for
5min followed by 30–40 cycles at 95 ◦C for 30 s, annealing at exon
speciﬁc temperature (available upon request) for 45 s, 72 ◦C for 30 s
with a ﬁnal 5min extension at 72 ◦C.
DHPLC was performed on a WAVE analysis system (Transge-
nomic, Omaha, NE) using different temperature conditions
(available upon request). Brieﬂy, PCR products were mixed in
approximately equimolar proportions with an ampliﬁed sample
known to contain a wild-type CYBB fragment, then denatured at
94 ◦C for 5min and then cooled at room temperature, to allow het-
eroduplex formation. Eachsamplewere runonaDnaSept.Mcolumn
(Transgenomics) andmonitored by ultraviolet light (260nm). Opti-
mumDHPLC temperatureswere detectedusing software-predicted
melting proﬁle as a starting point. Samples were run at a mean
of three temperatures due to the heterogeneity in the distribution
of GC-rich regions (Xiao and Oefner, 2001). Each elution chro-
matographic proﬁle was compared with proﬁles associated with
homozygous wild-type sequence. Samples with an altered chro-
matographic proﬁle were sequenced.
Direct sequencing was performed after purifying PCR products
with QIAquick PCR puriﬁcation kit (QIAGEN, Hilden, Germany).
Both strands were sequenced using the BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and ana-
lyzedonanABIPRISM3130and310automatedsequencers (Applied
Biosystems, Foster City, CA).
For the detection of GT homozygous deletion in exon 2 of NCF-1
gene we used primers pair and PCR conditions already described
(Noack et al., 2001), which do not differentiate between NCF-1
and NCF1. DHPLC analysis revealed the homozygous proﬁle of the
patient 20 and the data was conﬁrmed by sequence.
2.4. RT-PCR
When required, total RNA was isolated from either mononu-
clear cells or EBV-transformed B lymphocytes of both CGD
patients and healthy individuals by using Trizol procedure
(Invitrogen, Life Technologies, Milano, Italy). Reverse tran-
scription was performed using a single reaction kit (Super-
script, Invitrogen, Life Technologies, Milano, Italy) according
to the manufacturer’s instructions. Three overlapping follow-
ing primer pairs were used for ampliﬁcation of the cDNA
(NM 000397.3): 1 for: 5′-ACTGGGCTGTGAATGAGGG-3′; 5 rev: 5′-
CCATTCCACATTAAATAGATGTGC-3′; 3 for: 5′-GAAATCTGCTGTCC-
TTCCTCAG-3′; 8 rev: 5′-CCTTCTGTTGAGATCGCCA-3′; 7 for: 5′-GGA-
ATGCCCAATCCCTCAG-3′; 13 rev: 5′-GGGCCAGACTCAGAGTTGG-3′.
For the XK geneweused the following primer pairs: XK for: 5′-CAA-
CATGTTCTGCTGGTCTGCTGT-3′;XKrev:5′-AGAGAATGGCTGTGCAG-
TACCCAA-3′.
2.5. Immunoblot analysis
Lymphoblastoid cell lines or neutrophils from patients and
healthy controls were lysed on ice cold JS lysis buffer (50mM
Tris/HCl pH 8, 150mM NaCl, 1.5mM MgCl2, 5mM EGTA, 1% Triton-
X, 10% glycerol, 1mM PMSF, aprotinin 1mg/ml, leupeptin 1mg/ml,
pepstatin 1mg/ml, 1mM DTT) for 20min on ice and then clari-
ﬁed by centrifugation at 12,000 rpm for 10min at 4 ◦C. 25g of
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otal cell lysate was size-fractionated by SDS-PAGE gel and then
ransferred to nitrocellulose membrane (Protran by Schleicher &
chuell-Bioscience, Dassel, Germany). Membranes were blocked in
% milk for 1h at room temperature and then incubated, for 1h
t room temperature, with primary antibody (mAb48 kindly pro-
ided by Dr. D. Roos, Central Laboratory of the Netherlands Red
ross Blood Transfusion Service, Amsterdam). The speciﬁc binding
f the antibody to protein bandwas detected using goat anti-mouse
gG conjugated with horseradish peroxidase and visualized by ECL
LiteAblot by Euroclone SpA, Switzerland).
.6. FISH
FISH was performed on metaphase lymphoblastoid cell lines
reparations using the CGD region probe directly labelled with
pectrumOrange and an alpha X chromosome control probe (Qbio-
ene) labelled with ﬂuoroscein. The CYBB probe was DNA prepared
y a long PCR method using from exons 2–4, 4–8, 8–13 of the CYBB
egion as already described (Simon et al., 2005). DNAswere directly
abelled with Spectrum Orange (Vysis, Downer’s Grove, IL) by nick
ranslation andmixedwith COT-1 and all PCR products weremixed
s a probe cocktail for hybridizations. Ten metaphase chromosome
reparations with two positive X chromosome control probes were
cored for thepresenceof the test CGDprobe. Imageswere analyzed
ith a Zeiss Axioskop (New York, NY) microscope equipped with a
ytovision imaging system (Applied Imaging, Pittsburgh, PA). The
maging system allows for separate exposures of the ﬂuorochromes
hich assists in visualization of smaller red signal relative to the
arger control green ﬂuorochrome.
.7. Statistical analysis
Participating centers were required to register all consecutive
GD cases adopting a web-base data-base created by Oracle and
rotected by IANUS® Technology, implemented at Interuniversity
omputing Center (CINECA), in Bologna. Data were stored in a cen-
ral database, organized at the Associazione Italiana Ematologia
ncologia Pediatrica (AIEOP) Operation Ofﬁce.
Standard statistical descriptions of parameters were used to
haracterize the data (mean, median, and range). Fisher’s exact test
as used to comparedifferences in percentages for categorical vari-
bles, whereas Student’s t-test was adopted to compare means for
ontinuous variables.
The infection’s incidence rate per patient-year of follow-up for
ain infection categories was calculated overall and for each group
f mutation.
The measure of association used was the relative risk as esti-
ated by the odds ratio. Summary relative risks were computed
y the maximum likelihood method; a 95% conﬁdence interval was
alculatedbyuseof a test-basedestimationprocedure. A two-tailed
igniﬁcance test for trend was computed by the Mantel extension
f the Mantel–Haenszel procedure.
All P values were two-sided and values less than 0.05 were con-
idered statistically signiﬁcant. Analysis used December 31, 2007
s the reference date, i.e., the day at which all centers locked data
n patient outcomes. Computations were performed using STATA
ackage (StataCorp LP, College Station, TX, USA).
. Results and discussion
Thirty-three out of the 34 CGD patients included in the present
tudy had mutations in the CYBB gene (NG 009065), the remaining
YBB negative-CGD patient, had a GT homozygous deletion in exon
of NCF-1 gene encoding the p47phox protein, due to recombina-
ion events between NCF-1 and its two pseudogenes (NCF1) that
ontain GT deletion (Noack et al., 2001). All mutations are detailednology 46 (2009) 1935–1941 1937
in Table 1. Mutations are described using the HGVS gene number-
ing system where nucleotide +1 corresponds to the A of the ATG
initiation codon. The level of protein expression was documented
in the most of patients and indicated in Table 1.
The mutations were widely distributed over the CYBB gene
and affected both coding and non-coding regions. Nine out of
26 unique mutations found, were novel and submitted to XCGD
database (http://www.uta.ﬁ/imt/bioinfo/CYBBbase/), the other 17
had been previously published. All known mutations appear in the
X-CGDdatabasewith the relativeaccessionnumber referred toeach
detected patient and indicated in Table 1. The following nine novel
mutations were identiﬁed:
c.58G>A: missense mutation in exon 2, resulting in the already
described p.G20R amino acid change in the N-term domain, was
detected in the patient 12. Of interest this patient displayed an
extremely severe phenotype characterized by 2 episodes of brain
abscess and pneumonia, 1 liver and 1 gluteal abscess and a high
recurrence of dermatitis and gingivitis (21 and 20 episodes, respec-
tively). Furthermore at the age of 12 years he was diagnosed having
celiac disease.
c.1123G>T: non-sense mutation in exon 9, resulting in the
p.E375X amino acid change, introducing a premature stop codon in
the FADBD functional domain, was found in two unrelated patients
(pts. 9 and 10).
c.1357T>A: missense mutation in exon 11, resulting in the
already described W453R amino acid change in the NADPHBD
(causedbyc.1357T>C),wasdetected in twobrothers (pts. 18and19).
This mutation causes the substitution of a non-polar hydrophobic
amino acid with a positively charge and hydrophilic one. Interest-
ingly, the younger brother (pt. 19) was diagnosed at the age of
3 years because of severe and atypical infections while his older
brother (pt. 18) was diagnosed later on, only on the basis of bio-
chemical and molecular analysis but without symptoms of CGD
(Finocchi et al., 2008).
c.1076G>C: missense mutation in exon 9, causing the amino
acid change p.G359A in the FADBD functional domain, was found
in the patient 17. This mutation was found to be de novo. Phylo-
genetic comparison underlined that G359 is a highly conserved
residue (Rattus norvegicus, Gallus gallus, Xenopus tropicalis, Ciona
intestinalis, Danio rerio) reinforcing its involvement in the disease.
In this patient, the expression of gp91 subunit, tested in neutrophils
and lymphoblastoid cell lines, was highly reduced but not absent,
although residual ROS production was not observed.
c.184delT in exon 3, resulting in a frameshift at F62 with a pre-
mature stop codon at L66 (p.F62SfsX66), was found in patient 21.
The patient’s twin sisters were carriers of the same mutation. In
one of them the prenatal diagnosis allowed the identiﬁcation of a
newborn female carrier.
c.1287delT and c.1290delC: deletions of two non-contiguous
nucleotides was found in the patient 25. His mother was heterozy-
gous for both deletions in DNA isolated from peripheral leucocytes.
The analysis of the affected familypedigree revealed that themater-
nal grandmother, grandfather and maternal aunt were not carriers.
These two non-contiguous base pairs, are located within a region
with no evidence of repeated or palindromic sequences. Further-
more, neither the T deletion nor the A deletion have been reported
in CYBBbase. This evidence, excludes the possibility of amutational
hot spot in this site.We hypothesized that a de novo mutation in the
patient’s mother, or a single or double deletion in healthy mater-
nal grandfather germ line might have occurred (Lázaro et al., 1994;
Crow,2000;Dobrovolnyet al., 2005). Paternitywasconﬁrmedusing
commercial STRs kit (AMPF1STR®IdentiﬁlterTM, Applied Biosys-
tem).Microsatellite analysis indicated that affected allele is present
in proband’smother,maternal aunt andmaternal grandfather (data
not shown). However, the analysis of theDNA frommaternal grand-
father’s spermatozoa failed to detect the presence of the single or
1938 G. Di Matteo et al. / Molecular Immunology 46 (2009) 1935–1941
Table 1
Genotype and classiﬁcation of CGD patients.
pt. Age at diagnosis Carrier’s status Western blot analysis Exon intron cDNA change Accession nrs. on CYBBbase Protein change
Non-sense mutations
1 3 years m carrier X910 Ex 2 c.83 G>A (A0563) p.W28X
2 7 years – X910 Ex 2 c.127A>T (A0261) p.R43X
3 3 years m carrier X910 Ex 5 c.388C>T (A0065, A0113, A0267-272,
A0427-431, A0587, A0596)
p.R130X
4 10 years – X910 Ex 5 c.388C>T p.R130X
5 8 months m carrier X910 Ex 5 c.469C>T (A0074-75, A0095, A0098,
A0152, A0177, A0274-277,
A0433-434, A0565-568)
p.R157X
6 3 years – X910 Ex 7 c.691C>T (A0421-422) p.Q231X
7 10 months m carrier + st carrier X910 Ex 8 c.868C>T (A0045-46, A0145, A0159,
A0194,
A0198,A0288-289,A0443-453,
A0639)
p.R290X
8 13 years – X910 Ex 9 c.1006G>T (A0087-88, A0291) p.E336X
9 3 years m+a carriers n.d. Ex 9 c.1123G>T A0610 p.E375X
10 2 years m carrier X910 Ex 9 c.1123G>T A0610 p.E375X
Missense mutations
11 6 years m carrier + st carrier X910 Ex 1 c.1 A>G (A0242) p.M1V
12 2 years – X910 Ex 2 c.58 G>A A0647 p.G20R
13s 6 years m carrier X91− Ex 9 c.925G>A (A0101-102, A0368-372) p.E309K
14s 1 years m carrier X91− Ex 9 c.925G>A (A0101-102, A0368-372) p.E309K
15a 49 years m carrier X91− Ex 9 c.925G>A (A0101-102, A0368-372) p.E309K
16a 12 years m+1st +3 nieces carrier X91− Ex 9 c.925G>A (A0101-102, A0368-372) p.E309K
17 2 years m not carrier X91− Ex 9 c.1076G>C A0611 p.G359A
18 6 years m carrier+ st not carrier X910 Ex 11 c.1357T>A A0613 p.W453R
19 3 years m carrier+ st not carrier X910 Ex 11 c.1357T>A A0613 p.W453R
Deletion–duplication
20* 5 years A470 Ex2 c.73 74del 56 patients reported on
ncf1base
p.V25VfsX51
21* 16 years m carrier+ st1+ st2 carrier X910 Ex 3 c.184delT A0614 p.F62SfsX66
22 4 years m carrier n.d. Ex 6 c.484-100 674+291del p.N162 E225del
23 4 years – X910 Ex 7 c.675+? 804+?del p.R226 M268del
24 2 years – X910 Ex 7 c.755delG (A0219-220, A0195) p.G252EfsX254
25 3 years m carrier X910 Ex10 c.1287delT+ c.1290delC A0617 p.C428fs
26c 1 year – n.d. Ex 1-3 c.1+? 252+?del p.M1 A84del
27c 1 month – n.d. Ex 1-3 c.1+? 252+?del p.M1 A84del
28 2 years m carrier + st carrier X910 Ex 1–13 Del ≥550kb+XK gene –
29 4 years m not carrier X910 Ex 1–13 Del∼500kb –
30 2 years m carrier n.d. Ex 1 c.42 45dupCATT A0619 p.L16HfsX35
Splice site mutations
31 10 months m carrier X910 Int 2 c.141+5G>T A0615 r.46 141del
32 6 years m carrier n.d. Int 2 c.142-1G>A A0616 r.142 252del+wt
33 38 years m carrier;
st1 + st2 + st3 not
carriers; st4
carrier
X910 Ex 3 c.252G>A (A0022, A0127, A0063,
A0100,A0193, A0226-228,
A0230-231)
r.142 252del
34 23 years X910 Ex 3 c.252G>A (A0022, A0127, A0063, r.142 252del
I , a: au
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in bold patients with novel mutations are shown. m: mother; s: siblings; c: cousins
ouble deletion, thus allowing possible a de novo mutation in the
atient’s mother.
c.141+5G>T: splice-site mutation in intron 2, resulting in the
kipping of exon 2, was found in the patient 31. In this patient, the
xpression of the gp91 subunit in lymphoblastoid cell lines was
bsent.
c.142-1G>A: splice-site mutation in intron 2 was found in the
atient32. Thismutationcauses the skippingof exon3 thatdoesnot
enerate coding frameshift. cDNA analysis revealed the presence
f the exon 3 deleted cDNA form and a small amount of wild-type
DNA deriving from a residual normalmRNA splicing. However, the
atient’s family history revealed that two brothers deceased at the
ge of 2 months and 3 years, due to pulmonary disease and a third
ffected brother died at the age of 28 years due to lung aspergillosis.
his mutation was excluded in 100 healthy donors.
c.42 45 dupCATT: mutation in the 3′ end of exon 1 was detected
n the patient 30. His mother was heterozygous for the same muta-A0100,A0193, A0226-228,
A0230-231)
nt; st: sister and *: dead.
tion. cDNA analysis demonstrated that this duplication did not
affect the splicing of exon 1 but was conserved in the transcript
causing a frameshift at L16 with a premature stop codon at I35.
The remaining mutations have been previously reported and
indicated in the X-CGD mutation database (Roos, 1996; Heyworth
et al., 2001).
Particularly, we found six cases of deletions: two unrelated cases
(pts. 28 and 29) harbouring a deletion encompassing the whole
gene, two cousins (pts. 26 and 27) with a deletion including the
exons 1–3 (the upstream deletion breakpoint is under investiga-
tion), one case (pt. 22) with a 581bp deletion including the exon
6, one case where the deletion c.755delG resulted in a frameshift
with a premature stop codon at I254 (pt. 24) and the last one that
included exon 7 (pt. 23). The deletion breakpoints in the patients 28
and29have not been characterized, however in patient 28 the dele-
tion was large enough to affect from the adjacent XK gene (OMIM
+314850) whose lack is responsible of the Mc Leod syndrome,
Immunology 46 (2009) 1935–1941 1939
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ntil the SRPX gene (OMIM 300187), hypothetically involved in
he pathogenesis of retinitis pigmentosa. The length of the dele-
ionswas deduced amplifying speciﬁc genomic regions of the genes
ncluded in the short armof X chromosomeat Xp21whereCYBB, XK
nd SRPX genes reside (Peng et al., 2007). Of note, the patient 28 did
ot present signs or symptoms suggestive of retinitis pigmentosa
either of Mc Leod phenotype. He only displayed weak expression
f Kell erythrocyte antigens, differently from its normal expression
n pt. 29, and red cell acanthocytosis (Redman et al., 1999; Peng et
l., 2007).
With respect to the point mutations, we described a c.925G>A
issense mutation (p.E309K) in exon 9 in a large family with 4
ffected members (pts. 13–16). This mutation caused an X91− phe-
otypewith reduced gp91 expression.We also detected amissense
utation at the start codon of the gene (pt. 11). We found seven
on-sense mutations all reported in Table 1. We described a total
f seven CG→TG and CG→CA (pts. 3, 4, 5, 7, 13–16 related, 33,
4) transitions out of 19 single nucleotide substitutions (36.8%).
hese mutations are among the most frequent causes of human
enetic disease phenotypes due to the well known mechanism,
estricted to CpG dinucleotides, of methylation–deamination of
ytosine which leads to formation of thymidine. In our cohort,
he mutations c.388C>T, c.469C>T, c.868C>T, c.925G>A that involve
pG nucleotides, are respectively, already found in 16, 16, 20 and
patients reported in the CYBBbase. Moreover the mutations
.388C>T and c.252G>A are recurrent in our relatively little cohort,
hus reinforcing theprobability of a commonmolecularmechanism
n the onset of these mutations (Roos et al., 1996; Kannengiesser et
l., 2008). The splice-site mutation c.252G>A, in exon 3 adjacent to
ntron 3 of the CYBB gene, was found in two unrelated patients (pts.
3 and 34). This mutation, leading to exon 3 skipping in the most
f transcripts, was already described (Roos et al., 1996; Brunner et
l., 2007; Ishibashi et al., 2001; Kannengiesser et al., 2008).
In 20 families, after the identiﬁcation of the patient’s mutation,
e analyzed the X-CGD carrier status in mothers and female family
embers. Carrier detection revealed themutated gene in 90%of the
others with two de novo mutations representing 10% of the stud-
ed cases, similarly as seen in previous report (Rae et al., 1998). The
dentiﬁcation of carrier status in mothers of large deletion patients
8 and 29, was not carried out by sequencing because of ampliﬁca-
ion of normal copy of the gene in the homologous X chromosome.
his issue was addressed by FISH. As shown in Fig. 1, FISH analy-
is revealed that the mother of patient 28 was carrier of the large
eletion and microsatellites study conﬁrmed the same status for
is sister (data not shown).
Beside the heterogeneity of the mutations identiﬁed, a wide
ariability of the clinical phenotype related to the same muta-
ion was also found; i.e., siblings 13–14 and 18–19: onset of severe
nfections shortly after birth in patients 14 and 19 and absence of
linical manifestations in their older brothers (pts. 13 and 18) who
ere diagnosed later on, only once patients 14 and 19 were found
ffected.
Of interest, the only patient with AR-CGD who might be
xpected to have fewer infections and a mild phenotype
Winkelstein et al., 2000), showed instead a severe clinical history
nd died regardless the early institution of appropriate long-term
rophylaxis. Furthermore, in patient 29 the deletion encompassing
hewholegene results inamilderdiseasephenotype thanexpected.
Conversely, it is interesting the clinical similarity observed in
wo of the oldest unrelated patients (pts. 33 and 34) of our cohort,
ho presented the same splice site mutation c.252G>A. Both
atients showed a similar clinical phenotype (good clinical con-
itions still in adult age in absence of appropriate anti-infectious
rophylaxis) suggesting a correlation, probably due to residual ROS
roduction (Brunner et al., 2007), between this speciﬁc mutation
nd a leaky phenotype. However the analysis of the cDNA fromFig. 1. (A) Mother of the CGD patient 28: carrier. (B) Mother of the CGD patient 29:
non-carrier.
thesepatients failed todetectwild-typecDNAderiving fromaresid-
ual normal mRNA splicing.
In order to deﬁne a possible correlation between molecular
defect and clinical course of the disease, a retrospective survey of
patients from the time of diagnosis to December 2007 was car-
ried out. Clinical data were available for 29 patients: 3 with splice
mutation (pts. 31–33), 8 with missense (pts. 11–17, 19), 10 with
deletion (pts. 20–24, 26–30), and 8 with non-sense mutations (pts.
2–7, 8, 10), respectively. The infections were described according
to the site of infection and the infective agent when available. An
infection was considered severe when hospitalization or treatment
with parenteral antibiotics or antifungals was required. The fre-
quency and type of severe infections are shown in Table 2. At last
follow-up, the patients’ mean age was 16.1 years (median 15, range
1–42), mean duration of follow-up was 9.3 years while the total
period of observation was 271 years. The mean ages at ﬁrst infec-
tion and at diagnosis were not statistically different in the four
groups of patients. The rate of severe infections per patient-year,
did not signiﬁcantly vary in the four groups of mutations (P>0.05)
(Table 3) and no evidence of genotype–phenotype correlation was
detected, although all the deaths occurred in patients having dele-
tions. The molecular analysis of our series of patients with X-linked
CGD underlines the breadth and the heterogeneity of mutations
responsible for the disease.
It is likely that other factors may affect the clinical severity of
CGD such as polymorphisms in oxygen-independent antimicrobial
systems or other components of the immune system. However sys-
tematic characterization of molecular defect in larger cohorts of
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Table 2
Localization and type of severe infections in 29 CGD patients.
Infection Mutation
Splice N patients=3 Missense N patients=8 Deletion N patients=10 Non-sense N patients=8
Pneumonia 2 7 20 12
Lung abscess 0 0 1 0
Dermatitis 0 1 1 1
Subcutaneous abscess 0 0 1 4
Lymphadenitis 1 2 7 7
Septicemia 1 0 3 0
Colitis 0 0 0 1
Enteritis 1 0 0 1
Brain abscess 0 2 2 0
Liver abscess 1 1 4 3
Otitis 0 3 0 0
Kidney abscess 0 1 0 0
Osteomyelitis 0 0 3 1
Perianal abscess 1 1 0 1
Gluteal abscess 0 0 0 0
Luti 0 0 0 1
Total infections 7 18 42 32
Table 3
Patients characteristics and incidence of infections in the different groups of mutations.
Splice
(N patients 3)
Missense
(N patients 8)
Deletion
(N patients 10)
Non-sense
(N patients 8)
P
SvsM SvsD SvsN MvsD MvsN DvsN
N of total infections 11 79 52 43
N of severe infections 7 18 42 32
N of patient-years of observation 15 46 125 85
Mean age at 1◦ infection (months) 2.3 7.5 13.8 7.7 0.439 0.082 0.278 0.393 0.958 0.353
M .5
R .33
P year o
p
d
y
d
A
f
a
f
a
A
R
B
C
D
D
F
Gean age at diagnosis (years) 14.3 9.7 4
ate of severe infections per patient-year 0.46 0.39 0
-value <0.05 was considered statistically signiﬁcant. The infection rate per patient-
atients might help us to better relate clinical form and functional
ata to the type of the mutation found. In any case mutation anal-
sis remains an essential tool for genetic counselling and prenatal
iagnosis of CGD.
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